No mutations associated with Primary Hyperoxaluria Type 1 were identified. This result does not completely exclude PH1 if caused by variants in non-coding or regulatory regions. Clinical correlation with biochemical findings is advised.

PH1 is less likely but not entirely excluded. Further evaluation including urine glycolate levels and consideration of other genetic forms of hyperoxaluria may be warranted.

Two copies of the same pathogenic mutation were identified in the AGXT gene, consistent with a diagnosis of Primary Hyperoxaluria Type 1. This follows the classic autosomal recessive pattern of inheritance.

Confirms diagnosis of PH1. Genetic counselling is recommended. Treatment with pyridoxine may be considered depending on the specific mutation identified. Family members should be offered carrier testing.

Two different pathogenic mutations were identified on the two copies of the AGXT gene, consistent with a diagnosis of PH1.

Confirms diagnosis of PH1. Pyridoxine responsiveness depends on the specific variants identified. Combined liver-kidney transplantation may be considered in severe or refractory cases. Genetic counselling and family screening are recommended.

A single pathogenic mutation was identified in one copy of the AGXT gene. The individual is a carrier of PH1 and typically does not show symptoms but may have mildly elevated urinary oxalate.

Carrier status confirmed. Genetic counselling for family planning is recommended. Partner testing should be considered if there is a family history of PH1 or consanguinity.

A genetic variant was identified in the AGXT gene, but there is insufficient evidence currently available to classify it as pathogenic or benign.

Clinical correlation is essential. Additional family studies, functional assays, and periodic re-evaluation as new evidence becomes available are recommended. The variant may be reclassified over time.